Impact of a health safety warning on strontium ranelate utilization;Impacto de una alerta sanitaria sobre la utilización de ranelato de estroncio

Gaceta Sanitaria

Volumn 24, Issue 2, 2010, Pages 151-153

  Carracedo Martínez, Eduardo ^a   Pía Morandeira, Agustín ^a  

^a Servicio Gallego de Salud   (Spain)

Author keywords

Drug utilization; Osteoporosis; Strontium ranelate

Indexed keywords

ORGANOMETALLIC COMPOUND; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

ARTICLE; DRUG UTILIZATION; HOSPITAL INFORMATION SYSTEM; HUMAN; RETROSPECTIVE STUDY; SAFETY; SPAIN; STATISTICS;

DRUG UTILIZATION; HUMANS; MEDICAL ORDER ENTRY SYSTEMS; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; SAFETY; SPAIN; THIOPHENES;

EID: 77950051589     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2009.10.012     Document Type: Article

References (12)

1. Fuleihan G.E.H. Strontium ranelate -- a novel therapy for osteoporosis or a permutation of the same?. N Engl J Med. 350 (2004) 504-506
2. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 350 (2004) 459-468
3. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab. 90 (2005) 2816-2822
4. Díaz Curiel M., García J.J., Carrasco J.L., et al. Prevalencia de osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc). 116 (2001) 86-88
5. Dukes M.N.G. Drug utilization studies: methods and uses (1993), WHO Regional Publications, European Series p. 45
6. Peiró S., and Cervera P. Desde los AINE recomendados a la recomendacion de los AINE. Gac Sanit. 19 (2005) 486-491
7. Elizondo-López de Landache I., and Bracera-Izaguirre L. Influencia de una nota de seguridad emitida por la Agencia Española de Medicamentos y Productos Sanitarios en el uso de los principios activos tópicos pimecrolimus y tacrolimus. Pharm Care Esp. 10 (2008) 94-96
8. Mosquera Tenreiro C. Cambios en el uso de la terapia hormonal sustitutiva tras una intervención informativa dirigida a mujeres y prescriptores. Gac Sanit. 23 (2009) 100-103
9. Valiyeva E., Herrmann N., Rochon P.A., et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 179 (2008) 438-446
10. Wilkinson J.J., Force R.W., and Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy. 24 (2004) 978-986
11. Gleason P.P., Walters C., Heaton A.H., et al. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm. 13 (2007) 420-425
12. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14:523-531.